ロード中...
Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies have shown that HER2-positive cancer have different characteristics from other mammary tumors: a more rapid progression of the disease, an earlier age of onset (women of c...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AboutScience Srl
2018-10-01
|
| シリーズ: | AboutOpen |
| 主題: | |
| オンライン･アクセス: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/135 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|